bioAffinity Technologies, Inc. (BIAF) Form S-1 — Jun 12, 2026
bioAffinity Technologies (BIAF) has filed an S-1 registration statement to offer 2,631,579 shares of common stock and up to 2,631,579 pre-funded warrants at an assumed price of $1.52 per share. The offering is structured as a best-efforts placement with no minimum requirement, targeting approximately $3.4 million in net proceeds after fees. The capital raise is critical due to severe liquidity constraints; the company reported only $3.1 million in cash and a $72.2 million accumulated deficit as of March 31, 2026. Its auditor, WithumSmith+Brown, has issued a going-concern warning, stating that the company’s ability to continue operations is dependent on raising additional capital.
Key figures
- Revenue
- 6200000
- Total Debt
- 0
- Cash Position
- 3100000
- Gross Proceeds
- 4000000
- Offering Price
- 1.52
- Shares Offered
- 2631579
- Q1 2026 revenue
- 1400000
- Accumulated deficit
- 72200000
- Q1 2026 revenue growth yoy
- 146
- Placement agent fee percent
- 7.5
- Pre funded warrants offered
- 2631579
- Shares outstanding pre offering
- 4743061
- Placement agent warrants percent
- 3
- Shares outstanding post offering
- 7374640
- Placement agent legal reimbursement
- 120000
Price after filing
Close on the filing date to close N calendar days later (from $1.63). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.